Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. The lead program of Nicox’s ophthalmic pipeline, NCX 470, has successfully completed Phase 3 clinical development targeting glaucoma in the U.S. and China, with a separate Phase 3 program ongoing in Japan.

Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728. Nicox has two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis respectively. ZERVIATE is also commercialized in China.